Detection of rectal cancer and response to concurrent chemoradiotherapy by proton magnetic resonance spectroscopy

Min Ju Kim, Soon Jin Lee, Jung Hee Lee, Seung Hoon Kim, Ho Kyung Chun, Seong Hyun Kim, Hyo Keun Lim, Seong Hyeon Yun

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Introduction: To diagnose rectal cancer and monitor treatment response after preoperative concurrent chemoradiotherapy (CCRT) in rectal cancer patients using proton-1 magnetic resonance spectroscopy ( 1H-MRS). Materials and Methods: We enrolled 134 rectal cancer patients before treatment, of whom 34 underwent preoperative CCRT and follow-up MR spectroscopy before surgery. 1H-MRS was performed using a six-channel phased-array coil at 3.0 T. We evaluated the presence of a choline peak at 3.2 ppm, and lipid peaks at 0.9 and 1.3 ppm, and glutamine and glutamate peaks at 2.1-2.3 and 2.7 ppm seen at two TEs (40 and 135 ms). We divided MR spectra patterns into two groups (A and B). Results: A choline peak at 3.2 ppm seen in both TEs was characteristic for rectal cancer before treatment. Of 103 patients, 55 (53%) showed an elevated choline peak before treatment (type A). Type A spectra were seen in 68% of patients (23/34) before preoperative CCRT. After CCRT, the choline peak disappeared, resulting in only the lipid peak at 1.3 ppm (type B) in 97% of patients (33/34). Discussion: We optimized a localized in vivo 1H-MRS method for detection of rectal adenocarcinoma and monitoring treatment response after preoperative CCRT. The method appears to be a promising and feasible noninvasive modality.

Original languageEnglish
Pages (from-to)848-853
Number of pages6
JournalMagnetic Resonance Imaging
Volume30
Issue number6
DOIs
Publication statusPublished - 2012 Jul 1

Fingerprint

Chemoradiotherapy
Magnetic resonance spectroscopy
Rectal Neoplasms
Choline
Nuclear magnetic resonance
Lipids
Patient treatment
Therapeutics
Oncology
Glutamine
Surgery
Glutamic Acid
Protons
Adenocarcinoma
Magnetic Resonance Spectroscopy
Proton Magnetic Resonance Spectroscopy
Spectroscopy
Monitoring

Keywords

  • Concurrent chemoradiotherapy
  • MR spectroscopy
  • Rectal cancer

ASJC Scopus subject areas

  • Biophysics
  • Radiology Nuclear Medicine and imaging
  • Biomedical Engineering

Cite this

Detection of rectal cancer and response to concurrent chemoradiotherapy by proton magnetic resonance spectroscopy. / Kim, Min Ju; Lee, Soon Jin; Lee, Jung Hee; Kim, Seung Hoon; Chun, Ho Kyung; Kim, Seong Hyun; Lim, Hyo Keun; Yun, Seong Hyeon.

In: Magnetic Resonance Imaging, Vol. 30, No. 6, 01.07.2012, p. 848-853.

Research output: Contribution to journalArticle

Kim, Min Ju ; Lee, Soon Jin ; Lee, Jung Hee ; Kim, Seung Hoon ; Chun, Ho Kyung ; Kim, Seong Hyun ; Lim, Hyo Keun ; Yun, Seong Hyeon. / Detection of rectal cancer and response to concurrent chemoradiotherapy by proton magnetic resonance spectroscopy. In: Magnetic Resonance Imaging. 2012 ; Vol. 30, No. 6. pp. 848-853.
@article{6d73900aa5b24580babdb2030b361209,
title = "Detection of rectal cancer and response to concurrent chemoradiotherapy by proton magnetic resonance spectroscopy",
abstract = "Introduction: To diagnose rectal cancer and monitor treatment response after preoperative concurrent chemoradiotherapy (CCRT) in rectal cancer patients using proton-1 magnetic resonance spectroscopy ( 1H-MRS). Materials and Methods: We enrolled 134 rectal cancer patients before treatment, of whom 34 underwent preoperative CCRT and follow-up MR spectroscopy before surgery. 1H-MRS was performed using a six-channel phased-array coil at 3.0 T. We evaluated the presence of a choline peak at 3.2 ppm, and lipid peaks at 0.9 and 1.3 ppm, and glutamine and glutamate peaks at 2.1-2.3 and 2.7 ppm seen at two TEs (40 and 135 ms). We divided MR spectra patterns into two groups (A and B). Results: A choline peak at 3.2 ppm seen in both TEs was characteristic for rectal cancer before treatment. Of 103 patients, 55 (53{\%}) showed an elevated choline peak before treatment (type A). Type A spectra were seen in 68{\%} of patients (23/34) before preoperative CCRT. After CCRT, the choline peak disappeared, resulting in only the lipid peak at 1.3 ppm (type B) in 97{\%} of patients (33/34). Discussion: We optimized a localized in vivo 1H-MRS method for detection of rectal adenocarcinoma and monitoring treatment response after preoperative CCRT. The method appears to be a promising and feasible noninvasive modality.",
keywords = "Concurrent chemoradiotherapy, MR spectroscopy, Rectal cancer",
author = "Kim, {Min Ju} and Lee, {Soon Jin} and Lee, {Jung Hee} and Kim, {Seung Hoon} and Chun, {Ho Kyung} and Kim, {Seong Hyun} and Lim, {Hyo Keun} and Yun, {Seong Hyeon}",
year = "2012",
month = "7",
day = "1",
doi = "10.1016/j.mri.2012.02.013",
language = "English",
volume = "30",
pages = "848--853",
journal = "Magnetic Resonance Imaging",
issn = "0730-725X",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Detection of rectal cancer and response to concurrent chemoradiotherapy by proton magnetic resonance spectroscopy

AU - Kim, Min Ju

AU - Lee, Soon Jin

AU - Lee, Jung Hee

AU - Kim, Seung Hoon

AU - Chun, Ho Kyung

AU - Kim, Seong Hyun

AU - Lim, Hyo Keun

AU - Yun, Seong Hyeon

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Introduction: To diagnose rectal cancer and monitor treatment response after preoperative concurrent chemoradiotherapy (CCRT) in rectal cancer patients using proton-1 magnetic resonance spectroscopy ( 1H-MRS). Materials and Methods: We enrolled 134 rectal cancer patients before treatment, of whom 34 underwent preoperative CCRT and follow-up MR spectroscopy before surgery. 1H-MRS was performed using a six-channel phased-array coil at 3.0 T. We evaluated the presence of a choline peak at 3.2 ppm, and lipid peaks at 0.9 and 1.3 ppm, and glutamine and glutamate peaks at 2.1-2.3 and 2.7 ppm seen at two TEs (40 and 135 ms). We divided MR spectra patterns into two groups (A and B). Results: A choline peak at 3.2 ppm seen in both TEs was characteristic for rectal cancer before treatment. Of 103 patients, 55 (53%) showed an elevated choline peak before treatment (type A). Type A spectra were seen in 68% of patients (23/34) before preoperative CCRT. After CCRT, the choline peak disappeared, resulting in only the lipid peak at 1.3 ppm (type B) in 97% of patients (33/34). Discussion: We optimized a localized in vivo 1H-MRS method for detection of rectal adenocarcinoma and monitoring treatment response after preoperative CCRT. The method appears to be a promising and feasible noninvasive modality.

AB - Introduction: To diagnose rectal cancer and monitor treatment response after preoperative concurrent chemoradiotherapy (CCRT) in rectal cancer patients using proton-1 magnetic resonance spectroscopy ( 1H-MRS). Materials and Methods: We enrolled 134 rectal cancer patients before treatment, of whom 34 underwent preoperative CCRT and follow-up MR spectroscopy before surgery. 1H-MRS was performed using a six-channel phased-array coil at 3.0 T. We evaluated the presence of a choline peak at 3.2 ppm, and lipid peaks at 0.9 and 1.3 ppm, and glutamine and glutamate peaks at 2.1-2.3 and 2.7 ppm seen at two TEs (40 and 135 ms). We divided MR spectra patterns into two groups (A and B). Results: A choline peak at 3.2 ppm seen in both TEs was characteristic for rectal cancer before treatment. Of 103 patients, 55 (53%) showed an elevated choline peak before treatment (type A). Type A spectra were seen in 68% of patients (23/34) before preoperative CCRT. After CCRT, the choline peak disappeared, resulting in only the lipid peak at 1.3 ppm (type B) in 97% of patients (33/34). Discussion: We optimized a localized in vivo 1H-MRS method for detection of rectal adenocarcinoma and monitoring treatment response after preoperative CCRT. The method appears to be a promising and feasible noninvasive modality.

KW - Concurrent chemoradiotherapy

KW - MR spectroscopy

KW - Rectal cancer

UR - http://www.scopus.com/inward/record.url?scp=84861661583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861661583&partnerID=8YFLogxK

U2 - 10.1016/j.mri.2012.02.013

DO - 10.1016/j.mri.2012.02.013

M3 - Article

VL - 30

SP - 848

EP - 853

JO - Magnetic Resonance Imaging

JF - Magnetic Resonance Imaging

SN - 0730-725X

IS - 6

ER -